Ferrer Internacional S.A.
- Address
- Avinguda Diagonal 549
Sponsor Overview
Specializations
Progressive supranuclear palsy
Clinical research in progressive supranuclear palsy is centered on disease-modifying treatment development and long-term evaluation of motor and functional decline, with attention to neurological symptom progression and safety in adults living with this rare neurodegenerative disorder.
- PSP Rating Scale
- disease progression
- neurological function
The portfolio reflects interest in therapies aimed at slowing the clinical course of tau-related neurodegeneration and preserving daily functioning in people with PSP.
Amyotrophic lateral sclerosis
Research activity in amyotrophic lateral sclerosis focuses on treatment options for a progressive motor neuron disease, with emphasis on changes in functional status, symptom burden, and overall disease evolution in affected participants.
- motor neuron degeneration
- functional progression
- ALS therapy
This area highlights therapeutic interest in interventions intended to address the course of ALS and its impact on movement, strength, and independence.
Healthy volunteer studies
Studies in healthy volunteers support evaluation of pharmacokinetics, tolerability, and comparative product performance for orally administered treatments and fixed-dose combinations.
- bioequivalence
- fixed-dose combinations
- oral formulations
These investigations include comparative assessment of established cardiovascular and antiplatelet medicines in adult volunteers under controlled conditions.
Neurodegenerative disease therapeutics
The wider research landscape is concentrated on central nervous system disorders, especially conditions marked by progressive impairment of movement, coordination, and neurological performance.
- movement disorders
- clinical neurology
- symptom progression
Work in this domain supports therapeutic development for rare neurodegenerative diseases with unmet medical need.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Bioequivalence Study of Polypill AAR 100/80/10 mg Versus Aspirin 100 mg, Cardyl 80 mg, and Acovil 10 mg in Healthy Volunteers Under Fasting Conditions |  Romania | Not Recruiting |
| Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis: A Phase 3, Randomized, Double-blind, Placebo-controlled Study |  Belgium France Germany Ireland Italy Poland Spain Sweden The Netherlands | Recruiting |
| Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of FNP-223 in Progressive Supranuclear Palsy to Evaluate Efficacy and Safety | France Germany Hungary Italy Poland Portugal Spain | Not Recruiting |
Data & Insights
This sponsor works with 4 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 53 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases2 trials449 other sponsors
- 2.Cardiovascular Diseases1 trial359 other sponsors
Partnered Research Centres
53 centres- Address
- Str Centru Dn2 92 3, 727046 Cumparatura
- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Via Nicolo' Giustiniani 2, 35128 Padua
- Address
- Via Cherasco 15, 10126 Turin
- Address
- Largo Citta' D'ippocrate 1, 84131 Salerno
- Address
- Piazza Luigi Miraglia 2, 80138 Naples
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Ferrer Internacional S.A..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.